Soft Q2, FY 19 guidance now looks challenging
13/08/19 -"Novozymes reported soft Q2 19 numbers – missing street consensus but meeting our estimates. Sales were down 2% on an organic basis – driven by Agriculture & Feed and Food & ..."
Pages
50
Language
English
Published on
13/08/19
You may also be interested by these reports :
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...